Medicines Co
MDCO
MDCO was delisted on the 3rd of January, 2020.
202 hedge funds and large institutions have $3.5B invested in Medicines Co in 2017 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 90 increasing their positions, 66 reducing their positions, and 37 closing their positions.
54% more call options, than puts
Call options by funds: $114M | Put options by funds: $73.8M
36% more repeat investments, than reductions
Existing positions increased: 90 | Existing positions reduced: 66
8% less funds holding
Funds holding: 220 → 202 (-18)
14% less funds holding in top 10
Funds holding in top 10: 14 → 12 (-2)
22% less capital invested
Capital invested by funds: $4.52B → $3.5B (-$1.02B)
43% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 37
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Westfield Capital Management
Boston,
Massachusetts
|
+$81.8M |
| 2 |
PI
Putnam Investments
Boston,
Massachusetts
|
+$37.4M |
| 3 |
IAM
Iridian Asset Management
Westport,
Connecticut
|
+$29.2M |
| 4 |
BM
Bridger Management
New York
|
+$28.6M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$16.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BRC
Blue Ridge Capital
New York
|
-$53.8M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$48.8M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$39.6M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$32.6M |
| 5 |
RI
RTW Investments
New York
|
-$28M |
MDCO Hedge Fund Activity: Q2 2017 in Review
202 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Medicines Co (MDCO) for Q2 2017, worth a combined $3.5B — down 22% from $4.52B a quarter earlier.
Sellers outnumbered buyers: 37 funds closed out of MDCO and 21 opened new positions — a net loss of 16 holders — while 66 trimmed existing stakes and 90 added.
The largest buyer was Westfield Capital Management, adding an estimated $81.8M. The largest seller was Blue Ridge Capital, exiting entirely with an estimated $53.8M sold.
- 202 institutional investors held Medicines Co (MDCO) as of Q2 2017, down from 220 in Q1 2017.
- Funds reported $3.5B of Medicines Co stock for Q2 2017, down 22% quarter-over-quarter.
- 21 funds opened new Medicines Co positions in Q2 2017 and 37 closed out, a net change of -16 holders.
- The largest Medicines Co buyer in Q2 2017 was Westfield Capital Management, an estimated $81.8M added.
- The largest Medicines Co seller in Q2 2017 was Blue Ridge Capital, an estimated $53.8M sold.
Based on aggregated 13F filings for Q2 2017.